Article
Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.
European journal of haematology - 1 Nov 2024
Smith Elliot, Atenafu Eshetu G, Bankar Aniket, Chan Steven, Davidson Marta, Gupta Vikas, Minden Mark D, Richard-Carpentier Guillaume, Schimmer Aaron, Schuh Andre C, Sibai Hassan, Yee Karen, Maze Dawn
Abstract excerpt
Nucleophosmin-1 (NPM1)-mutated AML is a molecularly defined subtype typically associated with favorable treatment response and prognosis; however, its prognostic significance in AML evolving from an antecedent chronic myeloid malignancy is unknown. This study's primary objective was to determine the impact of mutated NPM1 on the prognosis of AML evolving from an antecedent chronic myeloid malignancy. We conducted...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.